JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1826
Concentrix
CNXC
$1.65B
| $14.2M | ﹤0.01% |
104,779
+5,467
| +6% | +$823K |
2020 Q4
6 quarters
|
|
1827
Editas Medicine
EDIT
$387M
| $14.2M | ﹤0.01% |
1,200,601
-55,960
| -4% | -$750K |
2017 Q1
21 quarters
|
|
1828
Globus Medical
GMED
$9.99B
| $14.2M | ﹤0.01% |
252,923
+43,110
| +21% | +$2.83M |
2015 Q4
26 quarters
|
|
1829
Smith & Nephew
SNN
$11.1B
| $14.2M | ﹤0.01% |
507,418
-269,392
| -35% | -$8.38M |
2014 Q2
32 quarters
|
|
1830
AerCap
AER
$22.6B
| $14.2M | ﹤0.01% |
345,919
+71,508
| +26% | +$3.31M |
2015 Q3
27 quarters
|
|
|
PACW
1831
DELISTED
PacWest Bancorp
PACW
| $14.2M | ﹤0.01% |
531,029
+60,604
| +13% | +$1.96M |
2013 Q2
36 quarters
|
|
1832
GitLab
GTLB
$8.32B
| $14.2M | ﹤0.01% |
266,408
-29,829
| -10% | -$1.39M |
2021 Q4
2 quarters
|
|
1833
PUT
Alcon
ALC
$30.9B
| $14.1M | ﹤0.01% |
202,200
-1,100
| -0.5% | -$80.3K |
2019 Q4
10 quarters
|
|
1834
Amdocs
DOX
$6.09B
| $14.1M | ﹤0.01% |
169,196
+84,028
| +99% | +$6.93M |
2022 Q1
1 quarter
|
|
|
ROSS
1835
DELISTED
Ross Acquisition Corp II
ROSS
| $14M | ﹤0.01% |
1,430,000
+531,000
| +59% | +$5.21M |
2021 Q2
4 quarters
|
|
|
CWEN.A
1836
DELISTED
Clearway Energy Class A
CWEN.A
| $14M | ﹤0.01% |
437,806
-199,952
| -31% | -$6.23M |
2015 Q2
28 quarters
|
|
1837
CALL
American International
AIG
$39.4B
| $14M | ﹤0.01% |
273,000
+130,300
| +91% | +$7.57M |
2021 Q2
4 quarters
|
|
1838
Unitil
UTL
$923M
| $13.9M | ﹤0.01% |
237,166
+65,119
| +38% | +$3.51M |
2013 Q2
36 quarters
|
|
|
HEP
1839
DELISTED
Holly Energy Partners, L.P.
HEP
| $13.9M | ﹤0.01% |
868,592
-68,690
| -7% | -$1.23M |
2013 Q2
36 quarters
|
|
|
ACH
1840
Accendra Health
ACH
$42.9M
| $13.9M | ﹤0.01% |
442,640
+163,330
| +58% | +$5.92M |
2013 Q2
36 quarters
|
|
1841
Brookfield Infrastructure
BIPC
$4.42B
| $13.9M | ﹤0.01% |
326,453
-111,177
| -25% | -$5.26M |
2020 Q2
8 quarters
|
|
|
BSX.PRA
1842
DELISTED
Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A
BSX.PRA
| $13.9M | ﹤0.01% |
136,783
+133,354
| +3,889% | +$14.5M |
2021 Q4
2 quarters
|
|
1843
Xencor
XNCR
$1.84B
| $13.9M | ﹤0.01% |
506,839
-2,775
| -0.5% | -$68.5K |
2013 Q4
34 quarters
|
|
|
ETRN
1844
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $13.9M | ﹤0.01% |
2,179,545
-1,188,328
| -35% | -$9.17M |
2018 Q4
14 quarters
|
|
1845
HF Sinclair
DINO
$20B
| $13.8M | ﹤0.01% |
306,620
-23,805
| -7% | -$1.07M |
2013 Q2
36 quarters
|
|
1846
ManpowerGroup
MAN
$2.62B
| $13.8M | ﹤0.01% |
181,002
-18,461
| -9% | -$1.62M |
2013 Q2
36 quarters
|
|
1847
PUT
SLB Ltd
SLB
$72.2B
| $13.8M | ﹤0.01% |
386,300
-65,000
| -14% | -$2.71M |
2014 Q2
32 quarters
|
|
|
DEA
1848
Easterly Government Properties
DEA
$1.1B
| $13.8M | ﹤0.01% |
289,978
+46,940
| +19% | +$2.29M |
2015 Q4
26 quarters
|
|
1849
CALL
Kinder Morgan
KMI
$68B
| $13.7M | ﹤0.01% |
818,700
+104,600
| +15% | +$1.96M |
2014 Q3
31 quarters
|
|
1850
Ingevity
NGVT
$2.44B
| $13.7M | ﹤0.01% |
216,529
-648
| -0.3% | -$42.2K |
2016 Q2
24 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.